The occurrence of hypoglycaemia in the treatment of Type 2 diabetes is also well recognized, but is more protean in nature, having different risk factors and clinical features according to the nature of the hypoglycaemic therapy, the extent of the insulin secretory deficit and the duration of diabetes. This evidence concerns the gene INS and type 2 diabetes mellitus.